Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Guilhufe – page 34

694 clinical trials in Guilhufe, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Guilhufe at a glance
694
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

694 trials in Guilhufe

Open in trial search

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Empagliflozin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Novo Nordisk A/S

Anxiety+1

Not recruiting

Comparison of oxazepam 50 mg orodispersible tablets and oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxazepam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Nicotine dependence

Not recruiting

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.

Systemic scleroderma+3

Not recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Artiva Biotherapeutics Inc.

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Guilhufe

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on Systemic Lupus Erythematosus (SLE) treatment evaluation, examining new therapeutic approaches for patients with moderate to severe manifestations of the disease.

  • Disease management strategies
  • Long-term safety assessment
  • Treatment efficacy evaluation

Studies aim to advance understanding of treatment responses in adults with active SLE despite ongoing therapy.

02 Cardiovascular Medicine

Advanced clinical research investigating stroke prevention in patients with atrial fibrillation, comparing innovative anticoagulation approaches.

  • Stroke prevention strategies
  • Bleeding risk assessment
  • Systemic embolism prevention

Comparative studies evaluating treatment efficacy and safety profiles in cardiac patients.

03 Infectious Diseases

Observational research examining mpox virus disease outcomes and treatment effectiveness, with particular focus on antiviral interventions.

  • Clinical outcome analysis
  • Antiviral treatment evaluation
  • Disease progression monitoring

Research aims to enhance understanding of treatment responses in infected patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.